drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00059 | DB06603 | 1,560 | 39 | [
"DDInter1404",
"DDInter1387"
] | Pegaspargase | Panobinostat | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Moderate | 1 | [
[
[
1560,
24,
39
]
],
[
[
1560,
24,
1247
],
[
1247,
23,
39
]
],
[
[
1560,
24,
912
],
[
912,
24,
39
]
],
[
[
1560,
63,
1257
],
[
1257,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Inter... |
DB00078 | DB11718 | 1,172 | 927 | [
"DDInter898",
"DDInter640"
] | Ibritumomab tiuxetan | Encorafenib | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
1172,
25,
927
]
],
[
[
1172,
25,
998
],
[
998,
24,
927
]
],
[
[
1172,
24,
1100
],
[
1100,
24,
927
]
],
[
[
1172,
25,
1259
],
[
1259,
... | [
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenylbutazone"
],
[
"... | Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Phenylbutazone and Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Venlafa... |
DB01005 | DB01155 | 995 | 872 | [
"DDInter894",
"DDInter813"
] | Hydroxyurea | Gemifloxacin | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Minor | 0 | [
[
[
995,
23,
872
]
],
[
[
995,
62,
739
],
[
739,
1,
872
]
],
[
[
995,
23,
956
],
[
956,
1,
872
]
],
[
[
995,
23,
945
],
[
945,
40,
... | [
[
[
"Hydroxyurea",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemifloxacin"
]
],
[
[
"Hydroxyurea",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
[
... | Hydroxyurea may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gemifloxacin (Compound)
Hydroxyurea may cause a minor interaction that can limit clinical effects when taken with Norfloxacin and Norfloxacin (Compound) resembles Gemifloxacin (Co... |
DB04868 | DB08868 | 478 | 1,011 | [
"DDInter1293",
"DDInter737"
] | Nilotinib | Fingolimod | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
478,
25,
1011
]
],
[
[
478,
6,
12523
],
[
12523,
45,
1011
]
],
[
[
478,
21,
29097
],
[
29097,
60,
1011
]
],
[
[
478,
62,
1247
],
[
124... | [
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Nilotinib",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Fingolimo... | Nilotinib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fingolimod (Compound)
Nilotinib (Compound) causes Eye pain (Side Effect) and Eye pain (Side Effect) is caused by Fingolimod (Compound)
Nilotinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfa... |
DB00305 | DB00552 | 377 | 1,238 | [
"DDInter1232",
"DDInter1425"
] | Mitomycin | Pentostatin | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of th... | A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | Moderate | 1 | [
[
[
377,
24,
1238
]
],
[
[
377,
21,
28769
],
[
28769,
60,
1238
]
],
[
[
377,
23,
1467
],
[
1467,
23,
1238
]
],
[
[
377,
23,
1539
],
[
1539... | [
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentostatin"
]
],
[
[
"Mitomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"{u} (Side Ef... | Mitomycin (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Pentostatin (Compound)
Mitomycin may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin may cause a minor interaction that can limit clinical effects when taken with Pe... |
DB08886 | DB14723 | 637 | 159 | [
"DDInter126",
"DDInter1026"
] | Asparaginase Erwinia chrysanthemi | Larotrectinib | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
637,
24,
159
]
],
[
[
637,
63,
322
],
[
322,
24,
159
]
],
[
[
637,
24,
484
],
[
484,
24,
159
]
],
[
[
637,
64,
1101
],
[
1101,
2... | [
[
[
"Asparaginase Erwinia chrysanthemi",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Asparaginase Erwinia chrysanthemi",
"{u} may cause a moderate interaction that could exacerbate diseases when ta... | Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerba... |
DB00524 | DB00581 | 811 | 355 | [
"DDInter1199",
"DDInter1018"
] | Metolazone | Lactulose | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Moderate | 1 | [
[
[
811,
24,
355
]
],
[
[
811,
63,
1647
],
[
1647,
1,
355
]
],
[
[
811,
21,
28750
],
[
28750,
60,
355
]
],
[
[
811,
24,
286
],
[
286,
... | [
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[
... | Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose (Compound) resembles Lactulose (Compound)
Metolazone (Compound) causes Abdominal discomfort (Side Effect) and Abdominal discomfort (Side Effect) is caused by Lactulose (Compound)
Metolazone may cause a moder... |
DB00372 | DB00543 | 999 | 87 | [
"DDInter1793",
"DDInter82"
] | Thiethylperazine | Amoxapine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Moderate | 1 | [
[
[
999,
24,
87
]
],
[
[
999,
24,
1119
],
[
1119,
1,
87
]
],
[
[
999,
63,
905
],
[
905,
40,
87
]
],
[
[
999,
63,
1174
],
[
1174,
1,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlordiazepoxide... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Chlordiazepoxide and Chlordiazepoxide (Compound) resembles Amoxapine (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Lorazepam and Lorazepam (Compound) resembles A... |
DB00350 | DB08931 | 1,214 | 947 | [
"DDInter1226",
"DDInter1600"
] | Minoxidil | Riociguat | A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. | Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurre... | Moderate | 1 | [
[
[
1214,
24,
947
]
],
[
[
1214,
24,
1344
],
[
1344,
24,
947
]
],
[
[
1214,
24,
1455
],
[
1455,
63,
947
]
],
[
[
1214,
24,
1344
],
[
1344,... | [
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Riociguat"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
[
... | Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Riociguat
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid and N... |
DB00661 | DB11581 | 122 | 1,456 | [
"DDInter1928",
"DDInter1926"
] | Verapamil | Venetoclax | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Major | 2 | [
[
[
122,
25,
1456
]
],
[
[
122,
25,
1135
],
[
1135,
23,
1456
]
],
[
[
122,
25,
1476
],
[
1476,
63,
1456
]
],
[
[
122,
24,
86
],
[
86,
... | [
[
[
"Verapamil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Verapamil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may c... | Verapamil may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Venetoclax
Verapamil may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interactio... |
DB00470 | DB00909 | 530 | 306 | [
"DDInter601",
"DDInter1971"
] | Dronabinol | Zonisamide | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This... | Moderate | 1 | [
[
[
530,
24,
306
]
],
[
[
530,
6,
8374
],
[
8374,
45,
306
]
],
[
[
530,
21,
28691
],
[
28691,
60,
306
]
],
[
[
530,
24,
1609
],
[
1609,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zonisamide"
]
],
[
[
"Dronabinol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Dronabinol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Zonisamide (Compound)
Dronabinol (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Zonisamide (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and... |
DB00502 | DB01619 | 1,300 | 830 | [
"DDInter853",
"DDInter1441"
] | Haloperidol | Phenindamine | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Moderate | 1 | [
[
[
1300,
24,
830
]
],
[
[
1300,
24,
537
],
[
537,
40,
830
]
],
[
[
1300,
63,
13
],
[
13,
24,
830
]
],
[
[
1300,
24,
104
],
[
104,
1... | [
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[... | Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Phenindamine (Compound)
Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction ... |
DB01073 | DB11627 | 1,488 | 1,367 | [
"DDInter745",
"DDInter860"
] | Fludarabine | Hepatitis B Vaccine (Recombinant) | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
1488,
24,
1367
]
],
[
[
1488,
63,
1648
],
[
1648,
24,
1367
]
],
[
[
1488,
75,
1064
],
[
1064,
24,
1367
]
],
[
[
1488,
24,
1480
],
[
14... | [
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Al... | Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Fludarabine (Compound) resembles Cladribine (Compound) and Fludarabine may lead to a m... |
DB00030 | DB06791 | 1,685 | 1,446 | [
"DDInter934",
"DDInter1021"
] | Insulin human | Lanreotide | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured ... | Moderate | 1 | [
[
[
1685,
24,
1446
]
],
[
[
1685,
24,
154
],
[
154,
63,
1446
]
],
[
[
1685,
24,
887
],
[
887,
24,
1446
]
],
[
[
1685,
24,
154
],
[
154,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
],
... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Pindolol and Pi... |
DB01583 | DB13928 | 624 | 1,385 | [
"DDInter1075",
"DDInter1660"
] | Liotrix | Semaglutide | Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal s... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
624,
24,
1385
]
],
[
[
624,
63,
1144
],
[
1144,
24,
1385
]
],
[
[
624,
1,
542
],
[
542,
24,
1385
]
],
[
[
624,
40,
1152
],
[
1152,
... | [
[
[
"Liotrix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Liotrix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
... | Liotrix may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Liotrix (Compound) resembles Levothyroxine (Compound) and Levothyroxine may cause a moderate interaction that co... |
DB00470 | DB00844 | 530 | 314 | [
"DDInter601",
"DDInter1257"
] | Dronabinol | Nalbuphine | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States. | Moderate | 1 | [
[
[
530,
24,
314
]
],
[
[
530,
24,
828
],
[
828,
40,
314
]
],
[
[
530,
63,
421
],
[
421,
1,
314
]
],
[
[
530,
63,
475
],
[
475,
25,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
],
[
... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Nalbuphine (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Nalbuphine (Compou... |
DB01112 | DB01390 | 665 | 1,117 | [
"DDInter335",
"DDInter1683"
] | Cefuroxime | Sodium bicarbonate | Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus. | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | Moderate | 1 | [
[
[
665,
24,
1117
]
],
[
[
665,
21,
28882
],
[
28882,
60,
1117
]
],
[
[
665,
63,
1127
],
[
1127,
23,
1117
]
],
[
[
665,
40,
1462
],
[
1462... | [
[
[
"Cefuroxime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Cefuroxime",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature in... | Cefuroxime (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Sodium bicarbonate (Compound)
Cefuroxime may cause a moderate interaction that could exacerbate diseases when taken with Nizatidine and Nizatidine may cause a minor interaction that can limit ... |
DB08938 | DB12455 | 1,384 | 933 | [
"DDInter1112",
"DDInter1336"
] | Magaldrate | Omadacycline | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in ani... | Moderate | 1 | [
[
[
1384,
24,
933
]
],
[
[
1384,
63,
417
],
[
417,
24,
933
]
],
[
[
1384,
24,
428
],
[
428,
63,
933
]
],
[
[
1384,
63,
417
],
[
417,
... | [
[
[
"Magaldrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omadacycline"
]
],
[
[
"Magaldrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
],
[
... | Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline
Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate an... |
DB06210 | DB14723 | 72 | 159 | [
"DDInter631",
"DDInter1026"
] | Eltrombopag | Larotrectinib | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
72,
24,
159
]
],
[
[
72,
24,
466
],
[
466,
23,
159
]
],
[
[
72,
24,
1412
],
[
1412,
63,
159
]
],
[
[
72,
63,
322
],
[
322,
24,
... | [
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
... | Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase p... |
DB00308 | DB12141 | 347 | 971 | [
"DDInter901",
"DDInter817"
] | Ibutilide | Gilteritinib | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Major | 2 | [
[
[
347,
25,
971
]
],
[
[
347,
23,
112
],
[
112,
23,
971
]
],
[
[
347,
25,
485
],
[
485,
24,
971
]
],
[
[
347,
25,
823
],
[
823,
63,... | [
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Ibutilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Ibutilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Ibutilide may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may ca... |
DB00030 | DB13873 | 1,685 | 1,534 | [
"DDInter934",
"DDInter719"
] | Insulin human | Fenofibric acid | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L128... | Moderate | 1 | [
[
[
1685,
24,
1534
]
],
[
[
1685,
24,
959
],
[
959,
24,
1534
]
],
[
[
1685,
63,
305
],
[
305,
24,
1534
]
],
[
[
1685,
24,
959
],
[
959,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenofibric acid"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase... |
DB00056 | DB05273 | 816 | 507 | [
"DDInter814",
"DDInter1638"
] | Gemtuzumab ozogamicin | Samarium (153Sm) lexidronam | Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheami... | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium ... | Major | 2 | [
[
[
816,
25,
507
]
],
[
[
816,
24,
248
],
[
248,
24,
507
]
],
[
[
816,
24,
270
],
[
270,
63,
507
]
],
[
[
816,
24,
850
],
[
850,
64,... | [
[
[
"Gemtuzumab ozogamicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Val... | Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate... |
DB09122 | DB14783 | 1,613 | 287 | [
"DDInter1409",
"DDInter574"
] | Peginterferon beta-1a | Diroximel fumarate | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
1613,
24,
287
]
],
[
[
1613,
63,
1101
],
[
1101,
24,
287
]
],
[
[
1613,
24,
1583
],
[
1583,
24,
287
]
],
[
[
1613,
64,
1510
],
[
1510,... | [
[
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when ta... |
DB01404 | DB06335 | 757 | 761 | [
"DDInter820",
"DDInter1646"
] | Ginseng | Saxagliptin | Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties. Ginseng is also known to contain phytoestrogens. | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
757,
24,
761
]
],
[
[
757,
24,
1296
],
[
1296,
63,
761
]
],
[
[
757,
63,
1179
],
[
1179,
24,
761
]
],
[
[
757,
64,
1419
],
[
1419,
... | [
[
[
"Ginseng",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Ginseng",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
... | Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro... |
DB00443 | DB08907 | 251 | 1,344 | [
"DDInter195",
"DDInter280"
] | Betamethasone | Canagliflozin | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
251,
24,
1344
]
],
[
[
251,
24,
549
],
[
549,
1,
1344
]
],
[
[
251,
6,
4973
],
[
4973,
45,
1344
]
],
[
[
251,
21,
29013
],
[
29013,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Betamethasone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Canagliflozin (Compound)
Betamethasone (Compound) causes Diabetes mellitus ... |
DB00056 | DB14409 | 816 | 1,129 | [
"DDInter814",
"DDInter867"
] | Gemtuzumab ozogamicin | Human adenovirus e serotype 4 strain cl-68578 antigen | Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheami... | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
816,
24,
1129
]
],
[
[
816,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
816,
24,
1683
],
[
1683,
24,
1129
]
],
[
[
816,
63,
1184
],
[
1184,
... | [
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Gemtuzumab ozogamicin",
"{u} may lead to a major life threatening interaction when t... | Gemtuzumab ozogamicin may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerb... |
DB00928 | DB11003 | 1,426 | 748 | [
"DDInter148",
"DDInter100"
] | Azacitidine | Anthrax vaccine | Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. ... | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
1426,
24,
748
]
],
[
[
1426,
25,
676
],
[
676,
63,
748
]
],
[
[
1426,
24,
1683
],
[
1683,
24,
748
]
],
[
[
1426,
64,
1057
],
[
1057,
... | [
[
[
"Azacitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Azacitidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"U... | Azacitidine may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Azacitidine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinum... |
DB00295 | DB01267 | 475 | 519 | [
"DDInter1244",
"DDInter1381"
] | Morphine | Paliperidone | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Major | 2 | [
[
[
475,
25,
519
]
],
[
[
475,
25,
1664
],
[
1664,
1,
519
]
],
[
[
475,
6,
12523
],
[
12523,
45,
519
]
],
[
[
475,
21,
28898
],
[
28898,
... | [
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paliperidone"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Risperidone"
],
[
"Risperidone",
"{u} (... | Morphine may lead to a major life threatening interaction when taken with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound)
Morphine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Paliperidone (Compound)
Morphine (Compound) causes Constipation (Side Effect) and Constipation (Side Ef... |
DB05294 | DB09020 | 1,069 | 28 | [
"DDInter1917",
"DDInter212"
] | Vandetanib | Bisacodyl | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
1069,
24,
28
]
],
[
[
1069,
21,
28666
],
[
28666,
60,
28
]
],
[
[
1069,
64,
739
],
[
739,
24,
28
]
],
[
[
1069,
25,
938
],
[
938,
... | [
[
[
"Vandetanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Vandetanib",
"{u} (Compound) causes {v} (Side Effect)",
"Nervous system disorder"
],
[
"Nervous system disorder",
... | Vandetanib (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Bisacodyl (Compound)
Vandetanib may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when ta... |
DB01030 | DB15762 | 869 | 725 | [
"DDInter1835",
"DDInter1644"
] | Topotecan | Satralizumab | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare au... | Moderate | 1 | [
[
[
869,
24,
725
]
],
[
[
869,
24,
1362
],
[
1362,
24,
725
]
],
[
[
869,
63,
372
],
[
372,
24,
725
]
],
[
[
869,
64,
1066
],
[
1066,
... | [
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Satralizumab"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
... | Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabi... |
DB01098 | DB01394 | 14 | 1,554 | [
"DDInter1622",
"DDInter431"
] | Rosuvastatin | Colchicine | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has ... | Major | 2 | [
[
[
14,
25,
1554
]
],
[
[
14,
6,
8374
],
[
8374,
45,
1554
]
],
[
[
14,
18,
2183
],
[
2183,
46,
1554
]
],
[
[
14,
18,
1918
],
[
1918,
... | [
[
[
"Rosuvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Colchicine"
]
],
[
[
"Rosuvastatin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Col... | Rosuvastatin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Colchicine (Compound)
Rosuvastatin (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is upregulated by Colchicine (Compound)
Rosuvastatin (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Colchicine (Compound)
Rosuvast... |
DB00938 | DB08907 | 455 | 1,344 | [
"DDInter1635",
"DDInter280"
] | Salmeterol | Canagliflozin | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
455,
24,
1344
]
],
[
[
455,
24,
549
],
[
549,
1,
1344
]
],
[
[
455,
6,
8374
],
[
8374,
45,
1344
]
],
[
[
455,
21,
28681
],
[
28681,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Salmeterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Canagliflozin (Compound)
Salmeterol (Compound) causes Hypersensitivity (Side Ef... |
DB00530 | DB01390 | 1,195 | 1,117 | [
"DDInter667",
"DDInter1683"
] | Erlotinib | Sodium bicarbonate | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | Moderate | 1 | [
[
[
1195,
24,
1117
]
],
[
[
1195,
21,
29093
],
[
29093,
60,
1117
]
],
[
[
1195,
24,
1220
],
[
1220,
23,
1117
]
],
[
[
1195,
24,
1468
],
[
... | [
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Erlotinib",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is ca... | Erlotinib (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Sodium bicarbonate (Compound)
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with S... |
DB00163 | DB00970 | 1,461 | 0 | [
"DDInter1943",
"DDInter466"
] | Vitamin E | Dactinomycin | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also d... | Moderate | 1 | [
[
[
1461,
24,
0
]
],
[
[
1461,
6,
5998
],
[
5998,
57,
0
]
],
[
[
1461,
23,
259
],
[
259,
63,
0
]
],
[
[
1461,
24,
1532
],
[
1532,
63... | [
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dactinomycin"
]
],
[
[
"Vitamin E",
"{u} (Compound) binds {v} (Gene)",
"HMOX1"
],
[
"HMOX1",
"{u} (Gene) is downregulated by {v} (Compo... | Vitamin E (Compound) binds HMOX1 (Gene) and HMOX1 (Gene) is downregulated by Dactinomycin (Compound)
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin
Vitamin E ma... |
DB00204 | DB08820 | 228 | 1,478 | [
"DDInter580",
"DDInter997"
] | Dofetilide | Ivacaftor | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
228,
24,
1478
]
],
[
[
228,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
228,
21,
28762
],
[
28762,
60,
1478
]
],
[
[
228,
24,
543
],
[
543,
... | [
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Dofetilide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Dofetilide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Dofetilide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperami... |
DB01193 | DB09340 | 819 | 1,013 | [
"DDInter12",
"DDInter1895"
] | Acebutolol | Tyropanoic acid | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Tyropanoic acid is a radiocontrast agent used in cholecystography, the X-ray diagnosis of gallstones under the trade names include Bilopaque, Lumopaque, Tyropaque, and Bilopac. The molecule contains three heavy iodine atoms which obstruct X-rays in the same way as the calcium in bones, which results in a visible image ... | Moderate | 1 | [
[
[
819,
24,
1013
]
],
[
[
819,
24,
777
],
[
777,
24,
1013
]
],
[
[
819,
40,
726
],
[
726,
24,
1013
]
],
[
[
819,
63,
1431
],
[
1431,
... | [
[
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tyropanoic acid"
]
],
[
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopromide"
],
... | Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Iopromide and Iopromide may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid
Acebutolol (Compound) resembles Betaxolol (Compound) and Betaxolol may cause a moderate interaction that coul... |
DB00197 | DB01181 | 1,324 | 1,532 | [
"DDInter1881",
"DDInter906"
] | Troglitazone | Ifosfamide | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
1324,
24,
1532
]
],
[
[
1324,
24,
1299
],
[
1299,
23,
1532
]
],
[
[
1324,
25,
246
],
[
246,
23,
1532
]
],
[
[
1324,
24,
255
],
[
255,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trovafloxacin"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Trovafloxacin and Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Ifosfamide
Troglitazone may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxaci... |
DB01128 | DB05239 | 918 | 866 | [
"DDInter204",
"DDInter425"
] | Bicalutamide | Cobimetinib | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Moderate | 1 | [
[
[
918,
24,
866
]
],
[
[
918,
24,
214
],
[
214,
63,
866
]
],
[
[
918,
63,
888
],
[
888,
24,
866
]
],
[
[
918,
64,
33
],
[
33,
24,
... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
... | Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen an... |
DB00359 | DB00563 | 161 | 663 | [
"DDInter1721",
"DDInter1174"
] | Sulfadiazine | Methotrexate | One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections. | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Moderate | 1 | [
[
[
161,
24,
663
]
],
[
[
161,
21,
28681
],
[
28681,
60,
663
]
],
[
[
161,
25,
126
],
[
126,
62,
663
]
],
[
[
161,
1,
1247
],
[
1247,
... | [
[
[
"Sulfadiazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Sulfadiazine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (... | Sulfadiazine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Methotrexate (Compound)
Sulfadiazine may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Methotre... |
DB00317 | DB11986 | 883 | 484 | [
"DDInter810",
"DDInter648"
] | Gefitinib | Entrectinib | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
883,
24,
484
]
],
[
[
883,
24,
998
],
[
998,
24,
484
]
],
[
[
883,
24,
242
],
[
242,
63,
484
]
],
[
[
883,
1,
594
],
[
594,
24,
... | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
],
[... | Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and... |
DB00900 | DB01024 | 45 | 1,096 | [
"DDInter544",
"DDInter1252"
] | Didanosine | Mycophenolic acid | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-termi... | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Moderate | 1 | [
[
[
45,
24,
1096
]
],
[
[
45,
7,
4456
],
[
4456,
46,
1096
]
],
[
[
45,
18,
7212
],
[
7212,
57,
1096
]
],
[
[
45,
21,
28996
],
[
28996,
... | [
[
[
"Didanosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Didanosine",
"{u} (Compound) upregulates {v} (Gene)",
"NOTCH1"
],
[
"NOTCH1",
"{u} (Gene) is upregulated ... | Didanosine (Compound) upregulates NOTCH1 (Gene) and NOTCH1 (Gene) is upregulated by Mycophenolic acid (Compound)
Didanosine (Compound) downregulates HMG20B (Gene) and HMG20B (Gene) is downregulated by Mycophenolic acid (Compound)
Didanosine (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal ... |
DB00687 | DB09420 | 870 | 1,074 | [
"DDInter747",
"DDInter953"
] | Fludrocortisone | Iodide I-123 | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect t... | Moderate | 1 | [
[
[
870,
24,
1074
]
],
[
[
870,
24,
1004
],
[
1004,
63,
1074
]
],
[
[
870,
63,
126
],
[
126,
24,
1074
]
],
[
[
870,
1,
251
],
[
251,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicyla... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate and Phenyl salicylate may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00047 | DB00783 | 176 | 1,438 | [
"DDInter932",
"DDInter679"
] | Insulin glargine | Estradiol | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Moderate | 1 | [
[
[
176,
24,
1438
]
],
[
[
176,
24,
1561
],
[
1561,
40,
1438
]
],
[
[
176,
24,
629
],
[
629,
63,
1438
]
],
[
[
176,
24,
245
],
[
245,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) resembles Estradiol (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interacti... |
DB00526 | DB01097 | 1,555 | 1,377 | [
"DDInter1355",
"DDInter1033"
] | Oxaliplatin | Leflunomide | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
1555,
25,
1377
]
],
[
[
1555,
6,
7950
],
[
7950,
45,
1377
]
],
[
[
1555,
63,
1461
],
[
1461,
23,
1377
]
],
[
[
1555,
24,
949
],
[
949,... | [
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Oxaliplatin",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Lefl... | Oxaliplatin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Leflunomide (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Leflunomide
Oxaliplatin may ca... |
DB01612 | DB09112 | 1,637 | 1,455 | [
"DDInter92",
"DDInter1306"
] | Amyl Nitrite | Nitrous acid | Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Its use as a prescription medicine comes from its ability to lower blood pressure. As an inhalant, it also has psychoactive effect which has led to illegal drug use. | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applica... | Major | 2 | [
[
[
1637,
25,
1455
]
],
[
[
1637,
25,
438
],
[
438,
24,
1455
]
],
[
[
1637,
24,
1549
],
[
1549,
24,
1455
]
],
[
[
1637,
63,
885
],
[
885,
... | [
[
[
"Amyl Nitrite",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nitrous acid"
]
],
[
[
"Amyl Nitrite",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avanafil"
],
[
"Avanafil",
"{u}... | Amyl Nitrite may lead to a major life threatening interaction when taken with Avanafil and Avanafil may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Nesiritide and Nesiritide may caus... |
DB01080 | DB11186 | 855 | 1,609 | [
"DDInter1933",
"DDInter1427"
] | Vigabatrin | Pentoxyverine | Vigabatrin is an analog of gamma-aminobutyric acid ([GABA]), the main inhibitory neurotransmitter in the central nervous system, used in the treatment of refractory seizures and infantile spasms. It irreversibly inhibits the enzyme responsible for GABA metabolism, thereby increasing levels of circulating GABA. Although... | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
855,
24,
1609
]
],
[
[
855,
63,
104
],
[
104,
24,
1609
]
],
[
[
855,
24,
649
],
[
649,
24,
1609
]
],
[
[
855,
63,
104
],
[
104,
... | [
[
[
"Vigabatrin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Vigabatrin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Vigabatrin may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Vigabatrin may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and... |
DB00065 | DB01394 | 581 | 1,554 | [
"DDInter923",
"DDInter431"
] | Infliximab | Colchicine | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has ... | Moderate | 1 | [
[
[
581,
24,
1554
]
],
[
[
581,
24,
367
],
[
367,
24,
1554
]
],
[
[
581,
25,
375
],
[
375,
63,
1554
]
],
[
[
581,
25,
168
],
[
168,
... | [
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colchicine"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfacon-1"
]... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Colchicine
Infliximab may lead to a major life threatening interaction when taken with Certolizumab peg... |
DB00024 | DB00222 | 818 | 245 | [
"DDInter1800",
"DDInter825"
] | Thyrotropin alfa | Glimepiride | Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cance... | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Moderate | 1 | [
[
[
818,
24,
245
]
],
[
[
818,
24,
959
],
[
959,
1,
245
]
],
[
[
818,
24,
5
],
[
5,
63,
245
]
],
[
[
818,
24,
1685
],
[
1685,
24,
... | [
[
[
"Thyrotropin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
]
],
[
[
"Thyrotropin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
... | Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Glimepiride (Compound)
Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interacti... |
DB01024 | DB09123 | 1,096 | 1,525 | [
"DDInter1252",
"DDInter546"
] | Mycophenolic acid | Dienogest | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Dienogest is an orally-active semisynthetic progestogen which also possesses the properties of 17α-hydroxyprogesterone. It is a derivative of 19-nortestosterone and has antiandrogenic properties. It is primarily used as a contraceptive in combination with ethinylestradiol, or in other combination form pills approved in... | Major | 2 | [
[
[
1096,
25,
1525
]
],
[
[
1096,
64,
1064
],
[
1064,
24,
1525
]
],
[
[
1096,
24,
1531
],
[
1531,
24,
1525
]
],
[
[
1096,
25,
375
],
[
375... | [
[
[
"Mycophenolic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dienogest"
]
],
[
[
"Mycophenolic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",... | Mycophenolic acid may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Dienogest
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakin... |
DB00705 | DB11691 | 441 | 1,499 | [
"DDInter496",
"DDInter1258"
] | Delavirdine | Naldemedine | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Moderate | 1 | [
[
[
441,
24,
1499
]
],
[
[
441,
63,
723
],
[
723,
24,
1499
]
],
[
[
441,
25,
1670
],
[
1670,
24,
1499
]
],
[
[
441,
25,
1406
],
[
1406,
... | [
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[... | Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Delavirdine may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cau... |
DB00738 | DB04855 | 485 | 540 | [
"DDInter1420",
"DDInter602"
] | Pentamidine | Dronedarone | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Major | 2 | [
[
[
485,
25,
540
]
],
[
[
485,
64,
347
],
[
347,
40,
540
]
],
[
[
485,
25,
33
],
[
33,
40,
540
]
],
[
[
485,
6,
8374
],
[
8374,
45,
... | [
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
]
],
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibutilide"
],
[
"Ibutilide",
"{u} ... | Pentamidine may lead to a major life threatening interaction when taken with Ibutilide and Ibutilide (Compound) resembles Dronedarone (Compound)
Pentamidine may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone (Compound) resembles Dronedarone (Compound)
Pentamidine (Compound) binds... |
DB01227 | DB06595 | 1,301 | 1,491 | [
"DDInter1043",
"DDInter1214"
] | Levacetylmethadol | Midostaurin | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Major | 2 | [
[
[
1301,
25,
1491
]
],
[
[
1301,
62,
112
],
[
112,
23,
1491
]
],
[
[
1301,
75,
888
],
[
888,
24,
1491
]
],
[
[
1301,
25,
1017
],
[
1017,
... | [
[
[
"Levacetylmethadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
],
[
[
"Levacetylmethadol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Levacetylmethadol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Levacetylmethadol (Compound) resembles Tamoxifen (Compound) and Levacetylmethadol may lead to a major ... |
DB00443 | DB06655 | 251 | 5 | [
"DDInter195",
"DDInter1077"
] | Betamethasone | Liraglutide | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
251,
24,
5
]
],
[
[
251,
40,
1103
],
[
1103,
23,
5
]
],
[
[
251,
24,
743
],
[
743,
23,
5
]
],
[
[
251,
63,
1252
],
[
1252,
23,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a ... | Betamethasone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril may cause a minor interaction that can... |
DB00726 | DB01064 | 1,164 | 1,148 | [
"DDInter1876",
"DDInter987"
] | Trimipramine | Isoprenaline | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Moderate | 1 | [
[
[
1164,
24,
1148
]
],
[
[
1164,
64,
1636
],
[
1636,
24,
1148
]
],
[
[
1164,
24,
480
],
[
480,
24,
1148
]
],
[
[
1164,
21,
28717
],
[
287... | [
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Trimipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenylephrine"
],
[
"P... | Trimipramine may lead to a major life threatening interaction when taken with Phenylephrine and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formotero... |
DB01233 | DB01320 | 1,311 | 651 | [
"DDInter1197",
"DDInter783"
] | Metoclopramide | Fosphenytoin | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Moderate | 1 | [
[
[
1311,
24,
651
]
],
[
[
1311,
63,
362
],
[
362,
1,
651
]
],
[
[
1311,
21,
28691
],
[
28691,
60,
651
]
],
[
[
1311,
62,
1479
],
[
1479,
... | [
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],... | Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Metoclopramide (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Fosphenytoin (Compound)
Metoclopramide may cause a minor... |
DB00543 | DB00748 | 87 | 662 | [
"DDInter82",
"DDInter297"
] | Amoxapine | Carbinoxamine | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Moderate | 1 | [
[
[
87,
24,
662
]
],
[
[
87,
63,
1594
],
[
1594,
24,
662
]
],
[
[
87,
6,
10104
],
[
10104,
45,
662
]
],
[
[
87,
21,
28921
],
[
28921,
... | [
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Amoxapine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Carbinoxamine (Compound)
Amoxapine (Compoun... |
DB00539 | DB05812 | 11 | 1,374 | [
"DDInter1837",
"DDInter8"
] | Toremifene | Abiraterone | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Major | 2 | [
[
[
11,
25,
1374
]
],
[
[
11,
6,
8374
],
[
8374,
45,
1374
]
],
[
[
11,
21,
28661
],
[
28661,
60,
1374
]
],
[
[
11,
25,
74
],
[
74,
6... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
]
],
[
[
"Toremifene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Abirat... | Toremifene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Abiraterone (Compound)
Toremifene (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effect) is caused by Abiraterone (Compound)
Toremifene may lead to a major life threatening interaction when taken with Boce... |
DB00903 | DB05351 | 1,680 | 101 | [
"DDInter686",
"DDInter519"
] | Etacrynic acid | Dexlansoprazole | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as ... | Dexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of , which is composed of a racemic mixture of the R- and S-enantiomers. Compared to the older generatio... | Moderate | 1 | [
[
[
1680,
24,
101
]
],
[
[
1680,
23,
1479
],
[
1479,
23,
101
]
],
[
[
1680,
63,
589
],
[
589,
24,
101
]
],
[
[
1680,
25,
361
],
[
361,
... | [
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Etacrynic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acetylsalicylic ... | Etacrynic acid may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Dexlansoprazole
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when tak... |
DB01068 | DB01233 | 1,565 | 1,311 | [
"DDInter411",
"DDInter1197"
] | Clonazepam | Metoclopramide | A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechan... | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
1565,
24,
1311
]
],
[
[
1565,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
1565,
63,
1010
],
[
1010,
23,
1311
]
],
[
[
1565,
63,
629
],
[
6... | [
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Clonazepam",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) i... | Clonazepam (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a minor interaction that can limit clinical effects when taken with Met... |
DB00222 | DB00930 | 245 | 166 | [
"DDInter825",
"DDInter432"
] | Glimepiride | Colesevelam | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Colesevelam is a bile acid sequestrant. Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood. It works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in th... | Moderate | 1 | [
[
[
245,
24,
166
]
],
[
[
245,
40,
959
],
[
959,
63,
166
]
],
[
[
245,
24,
1019
],
[
1019,
63,
166
]
],
[
[
245,
24,
1645
],
[
1645,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colesevelam"
]
],
[
[
"Glimepiride",
"{u} (Compound) resembles {v} (Compound)",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a modera... | Glimepiride (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Colesevelam
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that co... |
DB00224 | DB08881 | 215 | 868 | [
"DDInter917",
"DDInter1925"
] | Indinavir | Vemurafenib | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
215,
24,
868
]
],
[
[
215,
6,
8374
],
[
8374,
45,
868
]
],
[
[
215,
18,
8386
],
[
8386,
46,
868
]
],
[
[
215,
18,
4893
],
[
4893,
... | [
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Indinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Indinavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Indinavir (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Vemurafenib (Compound)
Indinavir (Compound) downregulates S100A13 (Gene) and S100A13 (Gene) is downregulated by Vemurafenib (Compound)
Indina... |
DB00358 | DB00564 | 1,010 | 1,236 | [
"DDInter1140",
"DDInter293"
] | Mefloquine | Carbamazepine | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Moderate | 1 | [
[
[
1010,
24,
1236
]
],
[
[
1010,
24,
508
],
[
508,
1,
1236
]
],
[
[
1010,
63,
362
],
[
362,
1,
1236
]
],
[
[
1010,
24,
820
],
[
820,
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
... | Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Carbamazepine (Compound)
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Carbamazepine (Compound... |
DB00877 | DB04855 | 629 | 540 | [
"DDInter1678",
"DDInter602"
] | Sirolimus | Dronedarone | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Moderate | 1 | [
[
[
629,
24,
540
]
],
[
[
629,
63,
228
],
[
228,
40,
540
]
],
[
[
629,
24,
33
],
[
33,
40,
540
]
],
[
[
629,
6,
8374
],
[
8374,
45,
... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dofetilide"
],
[
... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Dofetilide and Dofetilide (Compound) resembles Dronedarone (Compound)
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone (Compound) resembles Dronedarone (Compound)
... |
DB01105 | DB09117 | 222 | 957 | [
"DDInter1665",
"DDInter1391"
] | Sibutramine | Paraldehyde | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Paraldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello. It is classified as a central nervous system (CNS) depressant and has also been found to be an effective anticonvulsant, hypnotic and sedative agent due to its CNS depressant properties. ... | Moderate | 1 | [
[
[
222,
24,
957
]
],
[
[
222,
63,
126
],
[
126,
23,
957
]
],
[
[
222,
25,
1264
],
[
1264,
24,
957
]
],
[
[
222,
63,
770
],
[
770,
2... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paraldehyde"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
... | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Paraldehyde
Sibutramine may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderat... |
DB01041 | DB01591 | 770 | 667 | [
"DDInter1789",
"DDInter1696"
] | Thalidomide | Solifenacin | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
770,
24,
667
]
],
[
[
770,
21,
28743
],
[
28743,
60,
667
]
],
[
[
770,
63,
112
],
[
112,
23,
667
]
],
[
[
770,
24,
774
],
[
774,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Thalidomide",
"{u} (Compound) causes {v} (Side Effect)",
"Atrial fibrillation"
],
[
"Atrial fibrillation",
"{u... | Thalidomide (Compound) causes Atrial fibrillation (Side Effect) and Atrial fibrillation (Side Effect) is caused by Solifenacin (Compound)
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effe... |
DB00402 | DB01254 | 1,407 | 1,213 | [
"DDInter685",
"DDInter484"
] | Eszopiclone | Dasatinib | Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_.[A179638,L6850] Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a ... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
1407,
24,
1213
]
],
[
[
1407,
6,
8374
],
[
8374,
45,
1213
]
],
[
[
1407,
18,
5415
],
[
5415,
46,
1213
]
],
[
[
1407,
7,
6829
],
[
6829... | [
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Eszopiclone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Eszopiclone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound)
Eszopiclone (Compound) downregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Dasatinib (Compound)
Eszopiclone (Compound) upregulates MALT1 (Gene) and MALT1 (Gene) is downregulated by Dasatinib (Compound)
Eszopiclone ... |
DB00582 | DB08899 | 1,622 | 129 | [
"DDInter1946",
"DDInter649"
] | Voriconazole | Enzalutamide | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
1622,
24,
129
]
],
[
[
1622,
24,
918
],
[
918,
1,
129
]
],
[
[
1622,
6,
8374
],
[
8374,
45,
129
]
],
[
[
1622,
7,
5774
],
[
5774,
... | [
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
... | Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Voriconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Voriconazole (Compound) upregulates SELL (Gene) and SE... |
DB00327 | DB09472 | 421 | 1,383 | [
"DDInter890",
"DDInter1693"
] | Hydromorphone | Sodium sulfate | Hydromorphone is a pure opioid, a semi-synthetic hydrogenated ketone derivative of [morphine] that has been available clinically since 1920. Structurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 a... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
421,
24,
1383
]
],
[
[
421,
24,
1311
],
[
1311,
24,
1383
]
],
[
[
421,
1,
828
],
[
828,
24,
1383
]
],
[
[
421,
40,
993
],
[
993,
... | [
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
... | Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Hydromorphone (Compound) resembles Oxycodone (Compound) and Oxycodone may cause a moderate intera... |
DB00539 | DB00916 | 11 | 112 | [
"DDInter1837",
"DDInter1202"
] | Toremifene | Metronidazole | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Minor | 0 | [
[
[
11,
23,
112
]
],
[
[
11,
6,
8374
],
[
8374,
45,
112
]
],
[
[
11,
21,
28692
],
[
28692,
60,
112
]
],
[
[
11,
64,
847
],
[
847,
23... | [
[
[
"Toremifene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]
],
[
[
"Toremifene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Toremifene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Metronidazole (Compound)
Toremifene (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Metronidazole (Compound)
Toremifene may lead to a major life threatening interaction when taken with Atomoxetine and ... |
DB00418 | DB08881 | 536 | 868 | [
"DDInter1650",
"DDInter1925"
] | Secobarbital | Vemurafenib | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
536,
24,
868
]
],
[
[
536,
6,
7950
],
[
7950,
45,
868
]
],
[
[
536,
21,
28658
],
[
28658,
60,
868
]
],
[
[
536,
62,
608
],
[
608,
... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Secobarbital",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compou... | Secobarbital (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Vemurafenib (Compound)
Secobarbital (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Vemurafenib (Compound)
Secobarbital may cause a minor interaction that can limit clinical effects when taken with Lidocaine and L... |
DB00041 | DB00531 | 1,648 | 450 | [
"DDInter38",
"DDInter456"
] | Aldesleukin | Cyclophosphamide | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Moderate | 1 | [
[
[
1648,
24,
450
]
],
[
[
1648,
24,
1001
],
[
1001,
40,
450
]
],
[
[
1648,
23,
956
],
[
956,
62,
450
]
],
[
[
1648,
25,
367
],
[
367,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclophosphamide"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mechlorethamine"
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine and Mechlorethamine (Compound) resembles Cyclophosphamide (Compound)
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Norfloxacin and Norfloxacin may cause a minor interac... |
DB00065 | DB10583 | 581 | 949 | [
"DDInter923",
"DDInter415"
] | Infliximab | Clostridium tetani toxoid antigen (formaldehyde inactivated) | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium... | Moderate | 1 | [
[
[
581,
24,
949
]
],
[
[
581,
25,
550
],
[
550,
24,
949
]
],
[
[
581,
25,
1093
],
[
1093,
63,
949
]
],
[
[
581,
24,
58
],
[
58,
24,... | [
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",... | Infliximab may lead to a major life threatening interaction when taken with Trastuzumab and Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Infliximab may lead to a major life threatening interaction when taken with... |
DB00035 | DB00635 | 1,314 | 1,573 | [
"DDInter507",
"DDInter1515"
] | Desmopressin | Prednisone | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release... | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Major | 2 | [
[
[
1314,
25,
1573
]
],
[
[
1314,
25,
175
],
[
175,
40,
1573
]
],
[
[
1314,
25,
251
],
[
251,
1,
1573
]
],
[
[
1314,
21,
28900
],
[
28900,... | [
[
[
"Desmopressin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prednisone"
]
],
[
[
"Desmopressin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
... | Desmopressin may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound)
Desmopressin may lead to a major life threatening interaction when taken with Betamethasone and Betamethasone (Compound) resembles Prednisone (Compound)
Desmopressin (... |
DB00241 | DB00295 | 288 | 475 | [
"DDInter257",
"DDInter1244"
] | Butalbital | Morphine | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Major | 2 | [
[
[
288,
25,
475
]
],
[
[
288,
40,
1269
],
[
1269,
63,
475
]
],
[
[
288,
24,
124
],
[
124,
63,
475
]
],
[
[
288,
24,
701
],
[
701,
2... | [
[
[
"Butalbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
]
],
[
[
"Butalbital",
"{u} (Compound) resembles {v} (Compound)",
"Methohexital"
],
[
"Methohexital",
"{u} may cause a moderate interaction... | Butalbital (Compound) resembles Methohexital (Compound) and Methohexital may cause a moderate interaction that could exacerbate diseases when taken with Morphine
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could... |
DB00704 | DB01095 | 267 | 671 | [
"DDInter1263",
"DDInter769"
] | Naltrexone | Fluvastatin | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to r... | Moderate | 1 | [
[
[
267,
24,
671
]
],
[
[
267,
24,
788
],
[
788,
40,
671
]
],
[
[
267,
24,
14
],
[
14,
63,
671
]
],
[
[
267,
6,
15705
],
[
15705,
45... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
[... | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin (Compound) resembles Fluvastatin (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction t... |
DB00277 | DB01210 | 1,031 | 668 | [
"DDInter1791",
"DDInter1050"
] | Theophylline | Levobunolol (ophthalmic) | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Levobunolol is a cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochloride salt) for treatment of glaucoma. It has a role as an antiglaucoma drug and a beta-adrener... | Major | 2 | [
[
[
1031,
25,
668
]
],
[
[
1031,
25,
461
],
[
461,
1,
668
]
],
[
[
1031,
24,
688
],
[
688,
25,
668
]
],
[
[
1031,
25,
699
],
[
699,
... | [
[
[
"Theophylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levobunolol"
]
],
[
[
"Theophylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} (C... | Theophylline may lead to a major life threatening interaction when taken with Levobunolol
Theophylline may lead to a major life threatening interaction when taken with Timolol and Timolol (Compound) resembles Levobunolol (Compound)
Theophylline may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00315 | DB08881 | 767 | 868 | [
"DDInter1969",
"DDInter1925"
] | Zolmitriptan | Vemurafenib | Zolmitriptan is a member of the triptan class of 5-hydroxytryptamine(5-HT)<sub>1B/1D/(1F)</sub> receptor agonists used to treat acute migraine.[A462, L12978] [Sumatriptan] was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. This led to the development of second-generation triptan... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
767,
24,
868
]
],
[
[
767,
6,
7950
],
[
7950,
45,
868
]
],
[
[
767,
18,
12106
],
[
12106,
57,
868
]
],
[
[
767,
21,
29015
],
[
29015,
... | [
[
[
"Zolmitriptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Zolmitriptan",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compou... | Zolmitriptan (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Vemurafenib (Compound)
Zolmitriptan (Compound) downregulates NT5DC2 (Gene) and NT5DC2 (Gene) is downregulated by Vemurafenib (Compound)
Zolmitriptan (Compound) causes Eosinophilia (Side Effect) and Eosinophilia (Side Effect) is caused by Vemurafe... |
DB01105 | DB01142 | 222 | 1,264 | [
"DDInter1665",
"DDInter593"
] | Sibutramine | Doxepin | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Major | 2 | [
[
[
222,
25,
1264
]
],
[
[
222,
63,
508
],
[
508,
24,
1264
]
],
[
[
222,
24,
649
],
[
649,
63,
1264
]
],
[
[
222,
63,
1405
],
[
1405,
... | [
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
... | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedano... |
DB00285 | DB14723 | 1,100 | 159 | [
"DDInter1927",
"DDInter1026"
] | Venlafaxine | Larotrectinib | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
1100,
24,
159
]
],
[
[
1100,
25,
222
],
[
222,
23,
159
]
],
[
[
1100,
24,
98
],
[
98,
24,
159
]
],
[
[
1100,
25,
11
],
[
11,
24,... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Venlafaxine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibu... | Venlafaxine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause... |
DB01009 | DB06441 | 935 | 936 | [
"DDInter1009",
"DDInter283"
] | Ketoprofen | Cangrelor | Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an act... | Moderate | 1 | [
[
[
935,
24,
936
]
],
[
[
935,
24,
477
],
[
477,
24,
936
]
],
[
[
935,
63,
305
],
[
305,
24,
936
]
],
[
[
935,
24,
738
],
[
738,
63,... | [
[
[
"Ketoprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cangrelor"
]
],
[
[
"Ketoprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
... | Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor
Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherich... |
DB00334 | DB01067 | 867 | 959 | [
"DDInter1326",
"DDInter826"
] | Olanzapine | Glipizide | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
867,
24,
959
]
],
[
[
867,
63,
245
],
[
245,
40,
959
]
],
[
[
867,
24,
1411
],
[
1411,
1,
959
]
],
[
[
867,
6,
8374
],
[
8374,
4... | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
... | Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound... |
DB00026 | DB04868 | 1,184 | 478 | [
"DDInter94",
"DDInter1293"
] | Anakinra | Nilotinib | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
1184,
24,
478
]
],
[
[
1184,
24,
1468
],
[
1468,
63,
478
]
],
[
[
1184,
24,
854
],
[
854,
24,
478
]
],
[
[
1184,
63,
305
],
[
305,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"P... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Nimodipine and Nimodipine ma... |
DB01001 | DB01611 | 688 | 1,487 | [
"DDInter1632",
"DDInter893"
] | Salbutamol | Hydroxychloroquine | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
688,
24,
1487
]
],
[
[
688,
24,
1520
],
[
1520,
25,
1487
]
],
[
[
688,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
688,
23,
1247
],
[
1247... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
],
... | Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Salbutamol (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compoun... |
DB00686 | DB06754 | 383 | 707 | [
"DDInter1424",
"DDInter471"
] | Pentosan polysulfate | Danaparoid | Pentosan polysulfate is a sulfated pentosyl polysaccharide with heparin-like properties. | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity t... | Moderate | 1 | [
[
[
383,
24,
707
]
],
[
[
383,
24,
1496
],
[
1496,
63,
707
]
],
[
[
383,
63,
1172
],
[
1172,
25,
707
]
],
[
[
383,
24,
1468
],
[
1468,
... | [
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danaparoid"
]
],
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ninteda... | Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with I... |
DB00317 | DB01764 | 883 | 805 | [
"DDInter810",
"DDInter469"
] | Gefitinib | Dalfopristin | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome ... | Moderate | 1 | [
[
[
883,
24,
805
]
],
[
[
883,
6,
8374
],
[
8374,
45,
805
]
],
[
[
883,
63,
1101
],
[
1101,
23,
805
]
],
[
[
883,
24,
283
],
[
283,
... | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Gefitinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Gefitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dalfopristin (Compound)
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Dalfopristin
Gefitinib may caus... |
DB00307 | DB00570 | 1,101 | 147 | [
"DDInter202",
"DDInter1936"
] | Bexarotene | Vinblastine | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Moderate | 1 | [
[
[
1101,
24,
147
]
],
[
[
1101,
24,
134
],
[
134,
24,
147
]
],
[
[
1101,
5,
11555
],
[
11555,
44,
147
]
],
[
[
1101,
6,
8374
],
[
8374,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine
Bexarotene (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Vinb... |
DB00697 | DB08899 | 876 | 129 | [
"DDInter1821",
"DDInter649"
] | Tizanidine | Enzalutamide | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debili... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
876,
24,
129
]
],
[
[
876,
24,
918
],
[
918,
1,
129
]
],
[
[
876,
21,
28703
],
[
28703,
60,
129
]
],
[
[
876,
23,
112
],
[
112,
... | [
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
... | Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Tizanidine (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Tizanidine may cause a minor interacti... |
DB00808 | DB01156 | 1,605 | 593 | [
"DDInter916",
"DDInter252"
] | Indapamide | Bupropion | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Moderate | 1 | [
[
[
1605,
24,
593
]
],
[
[
1605,
6,
8374
],
[
8374,
45,
593
]
],
[
[
1605,
21,
29220
],
[
29220,
60,
593
]
],
[
[
1605,
62,
126
],
[
126,
... | [
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Indapamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Indapamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bupropion (Compound)
Indapamide (Compound) causes Abdominal pain upper (Side Effect) and Abdominal pain upper (Side Effect) is caused by Bupropion (Compound)
Indapamide may cause a minor interaction that can limit clinical effects when taken with W... |
DB00687 | DB06688 | 870 | 1,430 | [
"DDInter747",
"DDInter1677"
] | Fludrocortisone | Sipuleucel-T | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Moderate | 1 | [
[
[
870,
24,
1430
]
],
[
[
870,
1,
175
],
[
175,
24,
1430
]
],
[
[
870,
25,
676
],
[
676,
63,
1430
]
],
[
[
870,
24,
1531
],
[
1531,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} m... | Fludrocortisone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Fludrocortisone may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction tha... |
DB00439 | DB01611 | 289 | 1,487 | [
"DDInter341",
"DDInter893"
] | Cerivastatin | Hydroxychloroquine | On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Cana... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
289,
24,
1487
]
],
[
[
289,
24,
663
],
[
663,
23,
1487
]
],
[
[
289,
24,
723
],
[
723,
24,
1487
]
],
[
[
289,
63,
168
],
[
168,
... | [
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
... | Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a minor interaction that can limit clinical effects when taken with Hydroxychloroquine
Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Aprepit... |
DB00073 | DB00242 | 1,394 | 1,064 | [
"DDInter1608",
"DDInter392"
] | Rituximab | Cladribine | Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences... | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Major | 2 | [
[
[
1394,
25,
1064
]
],
[
[
1394,
24,
1270
],
[
1270,
63,
1064
]
],
[
[
1394,
63,
1253
],
[
1253,
24,
1064
]
],
[
[
1394,
23,
1461
],
[
14... | [
[
[
"Rituximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
]
],
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
... | Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Cladribine
Rituximab may cause a moderate interaction that could exa... |
DB01234 | DB08916 | 1,220 | 26 | [
"DDInter513",
"DDInter32"
] | Dexamethasone | Afatinib | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal grow... | Moderate | 1 | [
[
[
1220,
24,
26
]
],
[
[
1220,
63,
883
],
[
883,
40,
26
]
],
[
[
1220,
6,
4973
],
[
4973,
45,
26
]
],
[
[
1220,
7,
4833
],
[
4833,
... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Afatinib (Compound)
Dexamethasone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Afatinib (Compound)
Dexamethasone (Compound) upregulates HSD17B11 (Gene) and HSD17B11 (G... |
DB00348 | DB01234 | 254 | 1,220 | [
"DDInter1300",
"DDInter513"
] | Nitisinone | Dexamethasone | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
254,
24,
1220
]
],
[
[
254,
24,
1573
],
[
1573,
1,
1220
]
],
[
[
254,
21,
29362
],
[
29362,
60,
1220
]
],
[
[
254,
24,
1072
],
[
1072,... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[... | Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) resembles Dexamethasone (Compound)
Nitisinone (Compound) causes Leukocytosis (Side Effect) and Leukocytosis (Side Effect) is caused by Dexamethasone (Compound)
Nitisinone may cause a moderate ... |
DB12130 | DB15233 | 1,017 | 1,650 | [
"DDInter1094",
"DDInter142"
] | Lorlatinib | Avapritinib | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Major | 2 | [
[
[
1017,
25,
1650
]
],
[
[
1017,
63,
1478
],
[
1478,
24,
1650
]
],
[
[
1017,
62,
1101
],
[
1101,
24,
1650
]
],
[
[
1017,
24,
159
],
[
159... | [
[
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor"... | Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Lorlatinib may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexaroten... |
DB00802 | DB08820 | 1,322 | 1,478 | [
"DDInter43",
"DDInter997"
] | Alfentanil | Ivacaftor | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
1322,
24,
1478
]
],
[
[
1322,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
1322,
21,
28762
],
[
28762,
60,
1478
]
],
[
[
1322,
24,
985
],
[
98... | [
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Alfentanil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Alfentanil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Alfentanil (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimert... |
DB00241 | DB11718 | 288 | 927 | [
"DDInter257",
"DDInter640"
] | Butalbital | Encorafenib | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
288,
24,
927
]
],
[
[
288,
24,
112
],
[
112,
23,
927
]
],
[
[
288,
1,
536
],
[
536,
24,
927
]
],
[
[
288,
24,
1491
],
[
1491,
24... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Butalbital (Compound) resembles Secobarbital (Compound) and Secobarbital may cause a moderate interaction t... |
DB00352 | DB09570 | 482 | 1,480 | [
"DDInter1814",
"DDInter1002"
] | Tioguanine | Ixazomib | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Moderate | 1 | [
[
[
482,
24,
1480
]
],
[
[
482,
24,
987
],
[
987,
63,
1480
]
],
[
[
482,
63,
440
],
[
440,
24,
1480
]
],
[
[
482,
24,
152
],
[
152,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR s... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen and Vibrio cholerae CVD 103-HgR strain live antigen may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Tioguanine may cause a moderate interact... |
DB00574 | DB00780 | 121 | 551 | [
"DDInter717",
"DDInter1440"
] | Fenfluramine | Phenelzine | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name o... | Major | 2 | [
[
[
121,
25,
551
]
],
[
[
121,
25,
1161
],
[
1161,
40,
551
]
],
[
[
121,
64,
73
],
[
73,
25,
551
]
],
[
[
121,
64,
80
],
[
80,
40,
... | [
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenelzine"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Selegiline"
],
[
"Selegiline",
"{... | Fenfluramine may lead to a major life threatening interaction when taken with Selegiline and Selegiline (Compound) resembles Phenelzine (Compound)
Fenfluramine may lead to a major life threatening interaction when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Ph... |
DB00072 | DB00495 | 550 | 139 | [
"DDInter1846",
"DDInter1961"
] | Trastuzumab | Zidovudine | Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth ... | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | Moderate | 1 | [
[
[
550,
24,
139
]
],
[
[
550,
24,
810
],
[
810,
63,
139
]
],
[
[
550,
24,
599
],
[
599,
24,
139
]
],
[
[
550,
25,
77
],
[
77,
63,
... | [
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
]
],
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"... | Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 and Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine
Trastuzumab may cause a moderate interaction that could exacerbate diseases when ta... |
DB00365 | DB06589 | 839 | 1,250 | [
"DDInter842",
"DDInter1400"
] | Grepafloxacin | Pazopanib | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Major | 2 | [
[
[
839,
25,
1250
]
],
[
[
839,
23,
112
],
[
112,
23,
1250
]
],
[
[
839,
25,
1151
],
[
1151,
24,
1250
]
],
[
[
839,
24,
455
],
[
455,
... | [
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pazopanib
Grepafloxacin may lead to a major life threatening interaction when taken with Sunitinib and Sunitinib may c... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.